First-pass extracted concept

calcium integrin-binding protein1

Candidate: toolkit item1 source documents3 linked claims
Live refresh every 5sNext refresh in 5s

Aliases

calcium integrinbinding protein1, CIB1

Evidence Snippets

Because calcium integrin-binding protein1 lacks a suitable pocket that could be used to create a chemical inhibitor... Currently, no FDA-approved drugs are available for CIB1-driven cancer.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1structural functional progresssupports2022Source 1DOIPubMed

Improved understanding of CIB1 structure and function has enabled the design of several therapeutic candidates.

Quoted textsource-backed
The structure and function of the newly discovered calcium integrinbinding protein1 have been improved, paving the way for the designing of several therapeutic candidates.
Claim 2target druggability challengesupports2022Source 1DOIPubMed

CIB1 is a challenging drug target because it lacks a suitable pocket for creating a chemical inhibitor and is highly resistant to small inhibitors.

Quoted textsource-backed
Because calcium integrin-binding protein1 lacks a suitable pocket that could be used to create a chemical inhibitor... CIB1 has proven to challenge drug target due to several factors, including the fact that the CIB1 protein is highly resistant to small inhibitors.
Claim 3therapeutic landscape statussupports2022Source 1DOIPubMed

No FDA-approved drugs are available for CIB1-driven cancer.

Quoted textsource-backed
Currently, no FDA-approved drugs are available for CIB1-driven cancer.